Media & Resources

Aim is production of precursors to broadly neutralizing antibodies.

NEW YORK — OCTOBER 27, 2020 — IAVI announced today the award of US$26.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to support IAVI’s recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate. DTRA’s commitment will enable critical nonclinical development on the vaccine candidate that IAVI is developing…

Partners aim to provide potent neutralizing antibodies for COVID-19 pandemic response.

Organizations across the public and private sectors must join forces to make global access to transformative monoclonal antibody products a priority and a reality. The groups highlight four areas of action: Increase Awareness, Expand Availability, Apply Innovations, and Create New Business Models. The time to act is now to ensure equitable global access to potentially…

Antibody injections could offer HIV protection that would be of special value to women and girls in low-income countries.

New collaboration to leverage complementary expertise and capabilities with rVSV technology to advance novel vaccine candidate.

Japan's commitment to contribute to the World Bank for COVID-19 vaccine research sets example and will advance global health, IAVI says (in Japanese).

Government of Japan, in partnership with the World Bank, commits funds to COVID-19 vaccine development.